Figure S17 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

This is a Experimental Study study.

October 8, 2025Open Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

RAS pathway inhibitors showed effectiveness against tumor spheroids derived from different cancer types, suggesting broad therapeutic potential.
The sensitivity profiles analyzed across multiple cell types indicate marked variations in response to RAS inhibitors.
Assessment of multicell-type tumor spheroids allowed for detailed profiling of drug responses in oncogenic KRAS variant contexts.
These findings may inform future clinical strategies targeting RAS-driven tumor types, emphasizing the need for personalized treatment approaches.

Analysis reveals sensitivity profiles of tumor spheroids with oncogenic KRAS variants, indicating RAS inhibitors are effective.

Figure S17. Sensitivity profiles of the 19 multicell-type tumor spheroids from all RAS pathway inhibitor combinations.

No takes yet. Share an insight, caveat, or question.

Davoudi et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share